CompletedN/A

Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy

NCT06557239 · PAP_OXT · Tatiana Aboulafia Brakha

Closed to entry

Status

Not accepting participants

Not applicable

Phase

Target enrolment

Study sites

Outside the US

What it is testing

Summary

The main objective of this pilot study is to obtain preliminary data on the reactivity of salivary oxytocin during a single LSD intake as part of PAP treatment for anxiety disorders or depression (treatment authorisations granted in advance by the Federal Officie of Public Health for compassionate use of the substance). There will be no interference with the usual clinical routine in our Service. The protocol is only for taking additional saliva measurements to measure oxytocin levels on the day of treatment. Participants will be asked to give 4 saliva samples the day of their LSD treatment .In addition they will fill-in self-report questionnaires which are part of the clinical routine

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

Salivary oxytocin
Measured over the day of treatment administration (one day)

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 50 Years

Ages

All

Sex

Not accepted

Healthy volunteers

Inclusion Criteria: * ongoing psychotherapy with a certified psychotherapist, anxiety disorder or depression resistant to usual treatments, agreement to stop necessary medication Exclusion Criteria: * Exclusion: psychotic or bipolar disorder, high suicidal risk, severe cardiovascular disease, severe liver disease, neurological disease of the central nervous system, pregnancy and breastfeeding

Where

1 study site

Facility	City	Region	Country
Geneva University Hospitals	Geneva	—	Switzerland

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT06557239 on ClinicalTrials.gov →

Last updated in the registry 2025-05-16. Registry records change; this page reflects the data build of 2026-08-25.

Where this trial sits

Substance

Indication

Depression, Anxiety8